Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06384313
NA

Butyrate-enriched Triglyceride and Diabetes Prevention

Sponsor: Maastricht University Medical Center

View on ClinicalTrials.gov

Summary

A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. It has been shown that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. In this study it is hypothesized that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes.

Official title: Prevention of Diabetes with a Novel Butyrate-enriched Triglyceride

Key Details

Gender

All

Age Range

20 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2024-09-19

Completion Date

2027-09-01

Last Updated

2024-10-26

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

butyrate/hexanoate-enriched triglycerides

The oils are consumed two times a day for 24 weeks (six months).

Locations (1)

Maastricht University

Maastricht, Limburg, Netherlands